Kyowa Hakko Bio, a global leader in biotechnology and nutritional solutions, is thrilled to announce a groundbreaking collaboration with the Agency for ...

Kyowa Hakko Bio is thrilled to announce the grand opening of its expanded citicoline manufacturing facilities at the Kyowa Hakko Bio Yamaguchi Production Center...

KYOWA HAKKO BIO CO. LTD. (Kyowa Hakko Bio), a subsidiary of Kirin Holdings Company, Limited, is pleased to announce that it has received a no question letter from the United States’ Food and Drug Administration (FDA)...

KYOWA HAKKO BIO CO., LTD. (Kyowa Hakko Bio), a subsidiary of Kirin Holdings Company, Limited, is pleased to announce that its 6’-Sialyllactose sodium salt (6’-SL), a Human Milk Oligosaccharide (HMO), has been approved as a Novel Food...

Supersmart, a leading name in the field of dietary supplements and nutritional products, is proud to announce the launch of its groundbreaking product, Vision Postbiotic EYEMUSE®...

IMMUSE postbiotic for immune health, has been honored as the inaugural recipient of the the Ingredient of the Year: Microbiome Modulation category...

A new supplement concept to help you elevate your party recovery experience and unlock your body’s full potential in the days that follow.

Kyowa Hakko’s IMMUSE®, a clinically researched unique postbiotic, provides immune support in Lactoflor® Immuno 200...

KYOWA HAKKO BIO CO., LTD. (Kyowa Hakko Bio) is pleased to announce that its manufacturing strains used for producing 3'-sialyllactose (3’-SL) and 6’-sialyllactose (6’-SL) have passed the Chinese Ministry of Agriculture and Rural affairs’ (MARA) safety evaluation...

KYOWA HAKKO BIO CO. LTD. (Kyowa Hakko Bio), a subsidiary of Kirin Holdings Company, Limited (Kirin Holdings), completed a production facility for human milk oligosaccharides (HMOs) on November 18, 2022 at its Thai subsidiary, THAI KYOWA BIOTECHNOLOGIES CO., LTD.